Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Pradaxa Litigation Fines Upheld, Non-Monetary Sanctions Overturned February 6, 2014 Irvin Jackson Add Your Comments A federal appeals court has overturned some of the recent sanctions ordered in the Pradaxa litigation, finding that the judge presiding over the lawsuits can not force Boehringer Ingelheim employees from Germany to be deposed in the United States. However, monetary sanctions that require the drug maker to pay $1 million for bad faith conduct during discovery in the Pradaxa lawsuits were upheld on appeal. After finding that Boehringer Ingelheim withheld information during the discovery process and failed to preserve numerous files relevant to the lawsuits over bleeding problems from Pradaxa, U.S. District Judge David R. Herndon hit the drug maker with several sanctions in December 2013, including about $500 per case that is currently pending in the federal Multidistrict Litigation (MDL). Boehringer Ingelheim challenged the sanctions in the U.S. Court of Appeals for the Seventh Circuit, which issued an opinion (PDF) on January 24, ruling 2-to-1 that the non-monetary sanctions requiring more than a dozen of the company’s employees to be deposed in the United States were out of bounds. Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Judge Herndon currently presides over about 2,000 product liability lawsuits pending against Boehringer Ingelheim, which all involve similar allegations that the drug maker failed to provide adequate warnings about the risk of uncontrollable bleeding on Pradaxa, claiming that information was withheld from consumers and the medical community about the lack of a reversal agent for Pradaxa that would allow doctors to stop the blood thinning effects of the medication. As the parties prepare for the first Pradaxa trials in the MDL, which are set to begin in August, Judge Herndon ruled late last year that sanctions against Boehringer Ingelheim were appropriate because of bad faith actions during the litigation. In a case management order (PDF) issued late last year, Judge Herndon said the company’s excuses for lost data related to Pradaxa and employees who worked on the drug and its marketing bordered on the absurd, like claims that a hard drive was erased by a Windows 7 Operating System update, and that the company did not understand that it was facing significant Pradaxa litigation until August 2013. The appeals court ruling said there was little to question about Herndon’s decision to fine the company. However, the panel of judges called his decision to move depositions of Europe-based Boehringer Ingelheim employees from Amsterdam to the U.S. “deeply disturbing” and rejected that part of the sanctions. The opinion found that Judge Herndon’s sanctions would have led to the risk of international complications and the punishment of innocent Boehringer Ingelheim employees for no real benefit. However, one of the judges dissented, siding with Judge Herndon. “The district judge ordered a foreign corporation to produce its witnesses for depositions in the United States not as a matter of routine case management, but as a well-aimed sanction for repeated, bad-faith discovery abuses. No authority teaches that the sanction was even unreasonable, let alone unauthorized,” Seventh Circuit Appeals Judge David Hamilton wrote. “In fact, when properly understood, the district court’s sanction was superbly tailored to solve the problem the court faced. The defendant-petitioners had built a lengthy record of discovery abuses and failures showing that they and their lawyers were not taking the district court’s orders or their discovery obligations seriously.” Pradaxa Litigation Status The rulings come as Judge Herndon considers even more sanctions against Boehringer Ingelheim as discovery continues in preparation for a series of four trial dates that have been scheduled in the MDL between August 2014 and February 2015. As part of the coordinated pre-trial proceedings, Judge Herndon established an aggressive discovery schedule, indicating early in the litigation that it would benefit both plaintiffs and defendants for a quick determination to be made about the allegations raised in the cases. Last month, Judge Herndon identified four Pradaxa cases that will serve as “bellwether” trials, going before juries on August 11, 2014, November 3, 2014, January 5, 2015 and February 16, 2015. These early trial dates are designed to help the parties gauge how juries may respond to certain facts and testimony that may be offered throughout a large number of similar cases. The outcomes are designed to further Pradaxa settlement negotiations and potentially facilitate a resolution for the litigation. Pradadxa (dabigatran) is a Boehringer Ingelheim blood thinner approved by the FDA in October 2010. It was the first member of a new class of anticoagulants promoted as superior alternatives to warfarin, also known by the brand name Coumadin, for stroke prevention. However, shortly after its introduction, Pradaxa racked up a record number of adverse event reports after patients experienced uncontrolled bleeding events. Warfarin has been the go-to anticoagulant for decades. While Pradaxa does require less monitoring, concerns have emerged about the lack of an effective reversal agent to stop the blood thinning effects of the medication. Unlike warfarin, which can be quickly reversed with a dose of vitamin K and plasma, there is no available reversal agent for Pradaxa. While some studies have shown that the chances of bleeding may be about the same with the two drugs, evidence continues to emerge highlighting how Pradaxa bleeding problems may pose a more serious risk, since hemorrhages are typically harder to stop. Tags: Bleeding, Blood Thinner, Boehringer Ingelheim, Coumadin, Pradaxa, Warfarin Image Credit: | More Pradaxa Lawsuit Stories Jury Awards $540K in Pradaxa Trial Against Boehringer Ingelheim May 21, 2019 Paragard IUD Lawsuit Dismissed on Summary Judgment February 25, 2019 Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Link Between Hair Relaxers and Cancer To Be Examined by Court During “Science Day” (Posted: 2 days ago) A federal judge has called for Science Day presentations to explain to the court the theories and evidence linking hair relaxer to increased cancer risks. MORE ABOUT: HAIR RELAXER LAWSUITHair Relaxer Cancer Lawsuits Continue To Be Filed as Lawyers Prepare First Cases for Trial (06/24/2025)Replacement Hair Relaxer Lawsuit To Be Selected for MDL Bellwether Pool (06/12/2025)Hair Relaxer Lawsuits and Talcum Powder Lawsuits Designated as New Mass Torts in Philadelphia (05/30/2025) Lawyers Ordered To Engage in Talcum Powder Settlement Talks in MDL (Posted: 2 days ago) A special mediator has been appointed to oversee negotiations between Johnson & Johnson and tens of thousands of women who say its talcum powder products caused them to develop reproductive system cancers. MORE ABOUT: TALCUM POWDER LAWSUITSTalcum Powder Ovarian Cancer Lawsuit Selected for First Federal Bellwether Trial (07/01/2025)Retired Talcum Powder Judge May Be Appointed To Address Renewed Expert Motions (06/20/2025)Talc Safety To Be Subject of New Independent Scientific Expert Panel Led by FDA (05/22/2025) Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: 3 days ago) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)
Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018
Link Between Hair Relaxers and Cancer To Be Examined by Court During “Science Day” (Posted: 2 days ago) A federal judge has called for Science Day presentations to explain to the court the theories and evidence linking hair relaxer to increased cancer risks. MORE ABOUT: HAIR RELAXER LAWSUITHair Relaxer Cancer Lawsuits Continue To Be Filed as Lawyers Prepare First Cases for Trial (06/24/2025)Replacement Hair Relaxer Lawsuit To Be Selected for MDL Bellwether Pool (06/12/2025)Hair Relaxer Lawsuits and Talcum Powder Lawsuits Designated as New Mass Torts in Philadelphia (05/30/2025)
Lawyers Ordered To Engage in Talcum Powder Settlement Talks in MDL (Posted: 2 days ago) A special mediator has been appointed to oversee negotiations between Johnson & Johnson and tens of thousands of women who say its talcum powder products caused them to develop reproductive system cancers. MORE ABOUT: TALCUM POWDER LAWSUITSTalcum Powder Ovarian Cancer Lawsuit Selected for First Federal Bellwether Trial (07/01/2025)Retired Talcum Powder Judge May Be Appointed To Address Renewed Expert Motions (06/20/2025)Talc Safety To Be Subject of New Independent Scientific Expert Panel Led by FDA (05/22/2025)
Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: 3 days ago) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)